Showing 1 - 6 results of 6 for search '"риск-адаптированная терапия"', query time: 0.51s Refine Results
  1. 1
  2. 2
    Academic Journal

    Source: Cancer Urology; Том 15, № 2 (2019); 107-117 ; Онкоурология; Том 15, № 2 (2019); 107-117 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2019-15-2

    File Description: application/pdf

    Relation: https://oncourology.abvpress.ru/oncur/article/view/939/854; Hawkins D.S., Spunt S.L., Skapek S.X. COG Soft Tissue Sarcoma Committee. Children’s Oncology Group’s 2013 blueprint for research: Soft tissue sarcomas. Pediatr Blood Cancer 2013;60(6):1001–8. DOI:10.1002/pbc.24435.; Ritchey M.L., Shamberger R.C. Pediatric Urologic Oncology. In: Campbell-Walsh Urology. 10th edn. Ed.: A.J. Wein. Philadelphia: Elsevier Saunders, 2012. Pp. 3704–9.; Meza J.L., Anderson J., Pappo A.S. et al. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on Intergroup Rhabdomyosarcoma Studies III and IV. J Clin Oncol 2006;24(24):3844–51. DOI:10.1200/JCO.2005.05.3801.; Maurer H.M., Beltangady M., Gehan E.A. et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988;61(2):209–20.; Crist W.M., Anderson J.R., Meza J.L. et al. Intergroup rhabdomyosarcoma study-iv: results for patients with nonmetastatic disease. J Clin Oncol 2001;19(12):3091–102. DOI:10.1200/JCO.2001.19.12.3091.; Baker K.S., Anderson J.R., Link M.P. et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2000;18(12):2427–34. DOI:10.1200/JCO.2000.18.12.2427.; Raney R.B. Jr, Gehan E.A., Hays D.M. et al. Primary chemotherapy with or without radiation therapy and/or surgery for children with localized sarcoma of the bladder, prostate, vagina, uterus, and cervix. A comparison of the results in Intergroup Rhabdomyosarcom Studies I and II. Cancer 1990;66(10):2072–81.; Raney B., Anderson J., Jenney M. et al. Late effects in 164 patients with rhabdomyosarcoma of the bladder/prostate region: a report from the International Workshop. J Urol 2006;176(5):2190–5. DOI:10.1016/j.juro.2006.07.064.; Seitz G., Dantonello T.M., Int-Veen C. et al. Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal bladder/ prostate rhabdomyosarcoma: a report from the Cooperative Soft Tissue Sarcoma Trial CWS-96. Pediatr Blood Cancer 2011;56(5):718–24. DOI:10.1002/pbc.22950.; Oberlin O., Rey A., de Toledo J.S. et al. Randomized comparison of intensified sixdrug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapysensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol 2012;30(20):2457–65. DOI:10.1200/JCO.2011.40.3287.; Raney B., Stoner J., Anderson J. et al. Impact of tumor viability at second-look procedure before completing treatment on the Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV 1991–97: a report from the Children’s Oncology Group. J Pediatr Surg 2010;45:2160–8.; https://oncourology.abvpress.ru/oncur/article/view/939

  3. 3
  4. 4
  5. 5
  6. 6